Lonza Settles Patent Suits Vs. Axel and Stauber

Law360, New York (January 9, 2004, 12:00 AM EST) -- Swiss life-sciences company Lonza settled its patent infringement actions against Axel Chemicals LLC in and Stauber Performance Ingredients over a patent covering the production of solid oral dosage forms of the neutraceuticals L-carnitine L-tartrate for enteral administration.

L-carnitine is a nutrient beneficial for weight loss, athletic performance, and general cardiovascular health, according to Lonza.

Lonza had sued Axel Chemicals LLC in the U.S. District Court for the District of New Jersey in October 2002 and Stauber Performance Ingredients in the U.S. District Court for the Central...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.